Partnership / Collaboration · GCC · Announced 3 Nov 2025
IMGSA → Omani Investment
Algeria's IMGSA and an Omani pharma investment group agreed to build a US$20 million plant in Sohar Free Zone for antibiotics, oncology drugs and medical consumables, with trial production expected in 2027.
Parties: IMGSA (Algeria) → Omani Investment Group for Pharmaceutical Industry (Oman)
- Deal type
- Partnership / Collaboration
- Value
- $20m
- Territory
- Oman (Sohar Free Zone, 40,000 sq m site); phase one imports from Algeria
- Therapeutic area
- Multi-therapy
- Assets
- Antibiotics; Oncology treatments; Medical gloves; Sterile gauze and consumables
- Announced
- 3 Nov 2025
Our analysis
Why this matters
On 3 November 2025, Algeria's IMGSA complex and the Omani Investment Group for Pharmaceutical Industry signed a strategic partnership for joint investment and transfer of technology and expertise to build an integrated plant in Sohar Free Zone, Oman. The investment is US$20 million on a 40,000 square-metre site. Planned output includes antibiotics, oncology treatments, medical gloves, sterile gauze and other medical consumables. Phase one involves importing raw materials and finished products from Algeria; trial production is expected in 2027. Algeria's ambassador to Oman and Sohar port and free-zone officials attended the signing.
For CEOs: this is an unusual flow, with a North African manufacturer exporting know-how into the Gulf rather than the reverse. Our reading is that Oman's free-zone incentives are attracting Arab mid-sized manufacturers, not only multinationals.
The full analysis is free to read with a work email on this page.
Source: Souq Al Dawaa Saudi